0001493152-26-016827
SEC filingSelectis Health navigated a challenging fiscal 2025, achieving revenue growth and significantly narrowing its operating and net losses, while generating positive operating cash flow for the first time in the comparative period.
Revenue for fiscal 2025 increased to $41.4 million, a 4.9% year-over-year growth. This increase was primarily driven by healthcare operations, specifically due to increased Medicaid reimbursement rates at the company's facilities in Georgia and Oklahoma. This growth occurred despite a persistently challenging operating environment characterized by inflationary pressures, which management cites as a driver of increased operating costs. The revenue improvement is a positive signal, yet the company continues to operate at an operating loss, with an operating margin of -3.8% for the year.
The company made meaningful progress in reducing its losses in fiscal 2025. The operating loss narrowed significantly to $1.6 million, a 42.7% improvement from the prior year. Management attributes this improvement partly to a decrease in payroll costs following a reduction in general and administrative headcount. Similarly, the net loss improved by 58.1% to $1.0 million. This substantial improvement in bottom-line performance reflects the company's ongoing focus on cost discipline amidst inflationary headwinds. The path to sustained profitability, however, remains a critical challenge, as acknowledged by management's focus on increasing revenue and reducing costs as key objectives for continuing as a going concern.
A pivotal development in fiscal 2025 was the generation of positive cash flow from operations, which amounted to $1.9 million. This represents a significant positive swing from the prior year and resulted in positive free cash flow of $1.4 million after accounting for capital expenditures. This improvement in cash generation is a crucial step for a company that has historically experienced working capital shortages and relied on financing activities. Management states that short-term liquidity requirements are expected to be met from healthcare operations, rental revenues, and existing cash. However, the company's history of losses and reliance on external financing in the past underscores the ongoing importance of sustaining this positive cash flow trend.
Management concluded that disclosure controls and procedures were not effective as of December 31, 2025, due to a material weakness in internal control over financial reporting. The identified deficiency stems from insufficient resources to maintain adequate supervision and segregation of duties, a challenge noted as common for smaller companies. This weakness increases the risk of material misstatement in the company's financial reports. Management has stated plans to implement enhanced review procedures and work with third parties to strengthen controls. For investors, this represents a governance risk that affects the reliability of reported financial information.
Selectis Health continues to execute its strategic transition within the healthcare sector. The company faces intense competition and remains subject to extensive federal, state, and local healthcare regulations that could materially impact operations. Management's outlook and strategic reviews are based on estimates of future operating income, market trends, and expected cash flows from its properties. The company's ability to continue as a going concern is explicitly tied to its success in increasing revenue, reducing costs, achieving profitable operations, and obtaining any necessary additional financing. These objectives carry significant execution risk given the competitive and regulated operating environment and the company's historical financial performance.